The FDA granted accelerated approval to lifileucel (Amtagvi), a one-time, tumor-infiltrating lymphocyte (TIL) cell therapy made from a patient’s own immune cells, for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor. Lifileucel is manufactured by surgically removing a piece of the patient’s own tumor, isolating and expanding the T-cells that have already infiltrated it in a specialized lab process, then infusing billions of those expanded cells back into the patient after a lymphodepleting chemotherapy regimen — the first FDA-approved cellular therapy for a solid tumor of any kind. The approval was supported by the single-arm, open-label, multicohort C-144-01 trial (ClinicalTrials.gov NCT02360579); a pooled analysis of 153 patients across two of the trial’s cohorts (published in the Journal for ImmunoTherapy of Cancer, DOI 10.1136/jitc-2022-005755, PMID 36600653) reported an objective response rate of 31.4%, and the FDA’s own accelerated-approval decision rested specifically on the 73-patient efficacy-evaluable subset of that same trial’s cohort 4.

The FDA approved lisocabtagene maraleucel (Breyanzi), a CD19-directed CAR T-cell therapy that genetically engineers a patient’s own T-cells to target and kill cancer cells, for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy — the first and only FDA-approved CAR T-cell therapy for this cancer type, and Breyanzi’s fifth approved cancer type overall, the most of any CD19-directed CAR T-cell therapy. The approval was based on the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial (ClinicalTrials.gov NCT04245839), which enrolled adults with R/R MZL who had received at least 2 lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or who relapsed after stem cell transplantation; the intent-to-treat overall response rate was 84.4% with a 55.8% complete response rate.

The FDA granted accelerated approval to afamitresgene autoleucel (Tecelra) for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are positive for specific HLA-A*02 subtypes, and whose tumor expresses the MAGE-A4 antigen as confirmed by an FDA-approved or cleared companion diagnostic — reported as the first engineered cell therapy approved for a solid tumor in the United States. The approval was based on the single-arm, open-label, phase 2 SPEARHEAD-1 trial (ClinicalTrials.gov NCT04044768; primary publication in The Lancet, DOI 10.1016/S0140-6736(24)00319-2). Two overall-response-rate figures exist for this trial and both are preserved here rather than one being silently chosen: 43.2% in the 44-patient efficacy-evaluable analysis (the figure published in the FDA’s own Clinical Cancer Research approval summary, including a small number of complete responses) and approximately 39.4% in the larger 52-patient enrolled/intention-to-treat population. These are the same trial’s results reported against two different, both-legitimate denominators, not a factual disagreement to be resolved by picking one number. This is a single-arm response-rate result, not a randomized comparison, and accelerated approval means continued approval was contingent on confirmatory data. Cytokine release syndrome was common (reported in roughly three-quarters of patients, a small fraction severe) and carries a boxed warning; this is a one-time, individually manufactured cell therapy requiring leukapheresis and lymphodepleting chemotherapy beforehand, not an off-the-shelf drug, and eligibility is restricted to a genetically defined subset of synovial sarcoma patients (specific HLA-A*02 subtypes plus confirmed MAGE-A4 tumor expression) — most synovial sarcoma patients will not qualify. A separate report describing conversion to full/traditional FDA approval with an expanded pediatric (age 12+) indication in mid-2026 was found only in a company press release summary close to this record’s own review date and has not been independently confirmed against fda.gov directly.